Cathepsin B-cleavable Doxorubicin Prodrugs for Targeted Cancer Therapy (Review)

Overview

Journal Int J Oncol

Specialty Oncology

Date 2013 Jan 8

PMID 23291656

Citations 46

Authors

Yan-Jun Zhong

Li-Hua Shao

Yan Li

Affiliations

Soon will be listed here.

Abstract

Doxorubicin (DOX) is one of the most effective cytotoxic anticancer drugs used for the treatment of hematological malignancies, as well as a broad range of solid tumors. However, the clinical applications of this drug have long been limited due to its severe dose‑dependent toxicities. Therefore, DOX derivatives and analogs have been developed to address this issue. A type of DOX prodrug, cleaved by cathepsin B (Cat B), which is highly upregulated in malignant tumors and premalignant lesions, has been developed to achieve a higher DOX concentration in tumor tissue and a lower concentration in normal tissue, so as to enhance the efficacy and reduce toxicity to normal cells. In this review, we focused on Cat B-cleavable DOX prodrugs and discussed the efficacy of these prodrugs, demonstrated by preclinical and clinical developments.

Citing Articles

A novel multitargeted self-assembling peptide-siRNA complex for simultaneous inhibition of SARS-CoV-2-host cell interaction and replication.

Tuttolomondo M, Pham S, Terp M, Castillo V, Kalisi N, Vogel S Mol Ther Nucleic Acids. 2024; 35(3):102227.

PMID: 38939051 PMC: 11203390. DOI: 10.1016/j.omtn.2024.102227.

Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders.

Niazi S, Mariam Z, Magoola M Int J Mol Sci. 2024; 25(12).

PMID: 38928395 PMC: 11203520. DOI: 10.3390/ijms25126683.

Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity.

Cornelius P, Mayes B, Petersen J, Turnquist D, Dufour P, Dannenberg A Mol Cancer Ther. 2024; 23(5):595-605.

PMID: 38530115 PMC: 11063762. DOI: 10.1158/1535-7163.MCT-23-0574.

Low-frequency magnetic fields potentiate plasma-modified magneto-electric nanoparticle drug loading for anticancer activity in vitro and in vivo.

Mahdikia H, Saadati F, Alizadeh A, Khalighfard S, Bekeschus S, Shokri B Sci Rep. 2023; 13(1):17536.

PMID: 37845238 PMC: 10579258. DOI: 10.1038/s41598-023-44683-6.

Cathepsin B-activatable cyclic antisense oligonucleotides for cell-specific target gene knockdown and .

Wang Z, Fan X, Mu G, Zhao X, Wang Q, Wang J Mol Ther Nucleic Acids. 2023; 33:548-558.

PMID: 37588686 PMC: 10425675. DOI: 10.1016/j.omtn.2023.07.022.

References

David A, Kopeckova P, Rubinstein A, Kopecek J . Enhanced biorecognition and internalization of HPMA copolymers containing multiple or multivalent carbohydrate side-chains by human hepatocarcinoma cells. Bioconjug Chem. 2001; 12(6):890-9. DOI: 10.1021/bc010026v. View

Vicent M, Dieudonne L, Carbajo R, Pineda-Lucena A . Polymer conjugates as therapeutics: future trends, challenges and opportunities. Expert Opin Drug Deliv. 2008; 5(5):593-614. DOI: 10.1517/17425247.5.5.593. View

Rademaker-Lakhai J, Terret C, Howell S, Baud C, de Boer R, Pluim D . A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res. 2004; 10(10):3386-95. DOI: 10.1158/1078-0432.CCR-03-0315. View

Duncan R, Seymour L, Scarlett L, Lloyd J, Rejmanova P, Kopecek J . Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats. Biochim Biophys Acta. 1986; 880(1):62-71. DOI: 10.1016/0304-4165(86)90120-0. View

van der Schoot S, Nuijen B, Sood P, Thurmond 2nd K, Stewart D, Rice J . Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346. Pharmazie. 2006; 61(10):835-44. View

Meerum Terwogt J, Ten Bokkel Huinink W, Schellens J, Schot M, Mandjes I, Zurlo M . Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs. 2001; 12(4):315-23. DOI: 10.1097/00001813-200104000-00003. View

Castronovo V, Campo E, van den Brule F, Claysmith A, Cioce V, Liu F . Inverse modulation of steady-state messenger RNA levels of two non-integrin laminin-binding proteins in human colon carcinoma. J Natl Cancer Inst. 1992; 84(15):1161-9. DOI: 10.1093/jnci/84.15.1161. View

Rice J, Gerberich J, Nowotnik D, Howell S . Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res. 2006; 12(7 Pt 1):2248-54. DOI: 10.1158/1078-0432.CCR-05-2169. View

Nowotnik D, Cvitkovic E . ProLindac (AP5346): a review of the development of an HPMA DACH platinum Polymer Therapeutic. Adv Drug Deliv Rev. 2009; 61(13):1214-9. DOI: 10.1016/j.addr.2009.06.004. View

10.

Lotz M, Andrews Jr C, Korzelius C, Lee E, Steele Jr G, Clarke A . Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci U S A. 1993; 90(8):3466-70. PMC: 46321. DOI: 10.1073/pnas.90.8.3466. View

11.

Dubowchik G, Firestone R, Padilla L, Willner D, Hofstead S, Mosure K . Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem. 2002; 13(4):855-69. DOI: 10.1021/bc025536j. View

12.

Seymour L, Ferry D, Anderson D, Hesslewood S, Julyan P, Poyner R . Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol. 2002; 20(6):1668-76. DOI: 10.1200/JCO.2002.20.6.1668. View

13.

Etrych T, Jelinkova M, Rihova B, Ulbrich K . New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J Control Release. 2001; 73(1):89-102. DOI: 10.1016/s0168-3659(01)00281-4. View

14.

Satchi-Fainaro R, Mamluk R, Wang L, Short S, Nagy J, Feng D . Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell. 2005; 7(3):251-61. DOI: 10.1016/j.ccr.2005.02.007. View

15.

David A, Kopeckova P, Kopecek J, Rubinstein A . The role of galactose, lactose, and galactose valency in the biorecognition of N-(2-hydroxypropyl)methacrylamide copolymers by human colon adenocarcinoma cells. Pharm Res. 2002; 19(8):1114-22. DOI: 10.1023/a:1019885807067. View

16.

Podgorski I, Sloane B . Cathepsin B and its role(s) in cancer progression. Biochem Soc Symp. 2003; (70):263-76. DOI: 10.1042/bss0700263. View

17.

Minko T, Kopeckova P, Kopecek J . Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int J Cancer. 2000; 86(1):108-17. DOI: 10.1002/(sici)1097-0215(20000401)86:1<108::aid-ijc17>3.0.co;2-8. View

18.

Lin X, Zhang Q, Rice J, Stewart D, Nowotnik D, Howell S . Improved targeting of platinum chemotherapeutics. the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. Eur J Cancer. 2004; 40(2):291-7. DOI: 10.1016/j.ejca.2003.09.022. View

19.

Kovar M, Strohalm J, Etrych T, Ulbrich K, rihova B . Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect. Bioconjug Chem. 2002; 13(2):206-15. DOI: 10.1021/bc010063m. View

20.

Yeung T, Hopewell J, Simmonds R, Seymour L, Duncan R, Bellini O . Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat. Cancer Chemother Pharmacol. 1991; 29(2):105-11. DOI: 10.1007/BF00687318. View